Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mutation Patterns of DNA Repair Enzymes May Foretell Pancreatic Cancer Risk

By LabMedica International staff writers
Posted on 28 Jan 2009
Cancer researchers have found that the pattern of mutations in genes that produce DNA repair enzymes may be used to foretell increased or decreased risk of developing pancreatic cancer, depending on the genes involved.

As pancreatic cancer is often identified in late stages when it is resistant to most available therapies, there is considerable interest in characterizing genetic profiles that could be used to identify high-risk individuals for the purpose of prevention and early detection of this disease. More...


Toward this end, investigators at the University of Texas M. D. Anderson Cancer Center (Houston, USA) analyzed nine single nucleotide polymorphisms of seven DNA repair genes (LIG3, LIG4, OGG1, ATM, POLB, RAD54L, and RECQL) in 734 patients with pancreatic cancer and 780 healthy controls using the Taqman PCR (polymerase chain reaction) method for amplifying DNA expression. Information on cigarette smoking, alcohol consumption, medical history, and other risk factors was collected by personal interview. They reported in the January 15, 2009, issue of the journal Clinical Cancer Research that the presence of a homozygous mutant genotype of LIG3 G-39A was associated with a 77% reduction in the risk of pancreatic cancer. By contrast, the presence of the gene ATM D1853N was associated with a nearly threefold (255%) increased risk of pancreatic cancer.

"Currently, there is no approved genetic screening tool for pancreatic cancer," said first author Dr. Donghui Li, associate professor of gastrointestinal medical oncology at the M. D. Anderson Cancer Center. "Our study provides some preliminary data on one pattern of genetic variations that may be useful in determining risk. However, we still need to be cautious. As with any science, the key is replication, and the results of this study need to be confirmed by others."

Related Links:

University of Texas M. D. Anderson Cancer Center



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.